The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection
. Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD (Rabin Medical Center, Petah‐Tiqva, and Tel‐Aviv University, Tel‐Aviv, Israel). The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998; 244: 379–86. Objectives To test...
Saved in:
Published in | Journal of internal medicine Vol. 244; no. 5; pp. 379 - 386 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford BSL
Blackwell Science Ltd
01.11.1998
Blackwell Science Blackwell Publishing Ltd |
Subjects | |
Online Access | Get full text |
ISSN | 0954-6820 1365-2796 |
DOI | 10.1046/j.1365-2796.1998.00379.x |
Cover
Loading…
Abstract | . Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD (Rabin Medical Center, Petah‐Tiqva, and Tel‐Aviv University, Tel‐Aviv, Israel). The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998; 244: 379–86.
Objectives
To test whether empirical antibiotic treatment that matches the in vitro susceptibility of the pathogen (appropriate treatment) improves survival in patients with bloodstream infections; and to measure the improvement.
Design
Observational, prospective cohort study.
Setting
University hospital in Israel.
Subjects
All patients with bloodstream infections detected during 1988–94.
Interventions
None.
Main outcome measures
In‐hospital fatality rate and length of hospitalization.
Results
Out of 2158 patients given appropriate empirical antibiotic treatment, 436 (20%) died, compared with 432 of 1255 patients (34%) given inappropriate treatment (P = 0.0001). The median durations of hospital stay for patients who survived were 9 days for patients given appropriate treatment and 11 days for patients given inappropriate treatment. For patients who died, the median durations were 5 and 4 days, respectively (P < 0.05), for both comparisons.
In a stratified analysis, fatality was higher in patients given inappropriate treatment than in those given appropriate treatment in all strata but two: patients with infections caused by streptococci other than Streptococcus gr. A and Streptoccocus pneumoniae (odds ratio (OR) of 1.0, 95% confidence interval (95% CI) 0.4–2.5); and hypothermic patients (OR = 0.9, 95% CI = 0.3–2.4). Even in patients with septic shock, inappropriate empirical treatment was associated with higher fatality rate (OR = 1.6, 95% CI = 1.0–2.7). The highest benefit associated with appropriate treatment was observed in paediatric patients (OR = 5.1, 95% CI = 2.4– 10.7); intra‐abdominal infections (OR = 3.8, 95% CI = 2.0–7.1); infections of the skin and soft tissues (OR = 3.1, 95% CI = 1.8–5.6); and infections caused by Klebsiella pneumoniae (OR = 3.0, 95% CI = 1.7–5.1) and S. pneumoniae (OR = 2.6, 95% C = 1.1–5.9).
On a multivariable logistic regression analysis, the contribution of inappropriate empirical treatment to fatality was independent of other risk factors (multivariable adjusted OR = 1.6, 95% CI = 1.3–1.9).
Conclusion
Appropriate empirical antibiotic treatment was associated with a significant reduction in fatality in patients with bloodstream infection. |
---|---|
AbstractList | . Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD (Rabin Medical Center, Petah‐Tiqva, and Tel‐Aviv University, Tel‐Aviv, Israel). The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998; 244: 379–86.
Objectives
To test whether empirical antibiotic treatment that matches the in vitro susceptibility of the pathogen (appropriate treatment) improves survival in patients with bloodstream infections; and to measure the improvement.
Design
Observational, prospective cohort study.
Setting
University hospital in Israel.
Subjects
All patients with bloodstream infections detected during 1988–94.
Interventions
None.
Main outcome measures
In‐hospital fatality rate and length of hospitalization.
Results
Out of 2158 patients given appropriate empirical antibiotic treatment, 436 (20%) died, compared with 432 of 1255 patients (34%) given inappropriate treatment (P = 0.0001). The median durations of hospital stay for patients who survived were 9 days for patients given appropriate treatment and 11 days for patients given inappropriate treatment. For patients who died, the median durations were 5 and 4 days, respectively (P < 0.05), for both comparisons.
In a stratified analysis, fatality was higher in patients given inappropriate treatment than in those given appropriate treatment in all strata but two: patients with infections caused by streptococci other than Streptococcus gr. A and Streptoccocus pneumoniae (odds ratio (OR) of 1.0, 95% confidence interval (95% CI) 0.4–2.5); and hypothermic patients (OR = 0.9, 95% CI = 0.3–2.4). Even in patients with septic shock, inappropriate empirical treatment was associated with higher fatality rate (OR = 1.6, 95% CI = 1.0–2.7). The highest benefit associated with appropriate treatment was observed in paediatric patients (OR = 5.1, 95% CI = 2.4– 10.7); intra‐abdominal infections (OR = 3.8, 95% CI = 2.0–7.1); infections of the skin and soft tissues (OR = 3.1, 95% CI = 1.8–5.6); and infections caused by Klebsiella pneumoniae (OR = 3.0, 95% CI = 1.7–5.1) and S. pneumoniae (OR = 2.6, 95% C = 1.1–5.9).
On a multivariable logistic regression analysis, the contribution of inappropriate empirical treatment to fatality was independent of other risk factors (multivariable adjusted OR = 1.6, 95% CI = 1.3–1.9).
Conclusion
Appropriate empirical antibiotic treatment was associated with a significant reduction in fatality in patients with bloodstream infection. To test whether empirical antibiotic treatment that matches the in vitro susceptibility of the pathogen (appropriate treatment) improves survival in patients with bloodstream infections; and to measure the improvement.OBJECTIVESTo test whether empirical antibiotic treatment that matches the in vitro susceptibility of the pathogen (appropriate treatment) improves survival in patients with bloodstream infections; and to measure the improvement.Observational, prospective cohort study.DESIGNObservational, prospective cohort study.University hospital in Israel.SETTINGUniversity hospital in Israel.All patients with bloodstream infections detected during 1988-94.SUBJECTSAll patients with bloodstream infections detected during 1988-94.None.INTERVENTIONSNone.In-hospital fatality rate and length of hospitalization.MAIN OUTCOME MEASURESIn-hospital fatality rate and length of hospitalization.Out of 2158 patients given appropriate empirical antibiotic treatment, 436 (20%) died, compared with 432 of 1255 patients (34%) given inappropriate treatment (P = 0.0001). The median durations of hospital stay for patients who survived were 9 days for patients given appropriate treatment and 11 days for patients given inappropriate treatment. For patients who died, the median durations were 5 and 4 days, respectively (P < 0.05), for both comparisons. In a stratified analysis, fatality was higher in patients given inappropriate treatment than in those given appropriate treatment in all strata but two: patients with infections caused by streptococci other than Streptococcus gr. A and Streptoccocus pneumoniae (odds ratio (OR) of 1.0, 95% confidence interval (95% CI) 0.4-2.5); and hypothermic patients (OR = 0.9, 95% CI = 0.3-2.4). Even in patients with septic shock, inappropriate empirical treatment was associated with higher fatality rate (OR = 1.6, 95% CI = 1.0-2.7). The highest benefit associated with appropriate treatment was observed in paediatric patients (OR = 5.1, 95% CI = 2.4-10.7); intra-abdominal infections (OR = 3.8, 95% CI = 2.0-7.1); infections of the skin and soft tissues (OR = 3.1, 95% CI = 1.8-5.6); and infections caused by Klebsiella pneumoniae (OR = 3.0, 95% CI = 1.7-5.1) and S. pneumoniae (OR = 2.6, 95% C = 1.1-5.9). On a multivariable logistic regression analysis, the contribution of inappropriate empirical treatment to fatality was independent of other risk factors (multivariable adjusted OR = 1.6, 95% CI = 1.3-1.9).RESULTSOut of 2158 patients given appropriate empirical antibiotic treatment, 436 (20%) died, compared with 432 of 1255 patients (34%) given inappropriate treatment (P = 0.0001). The median durations of hospital stay for patients who survived were 9 days for patients given appropriate treatment and 11 days for patients given inappropriate treatment. For patients who died, the median durations were 5 and 4 days, respectively (P < 0.05), for both comparisons. In a stratified analysis, fatality was higher in patients given inappropriate treatment than in those given appropriate treatment in all strata but two: patients with infections caused by streptococci other than Streptococcus gr. A and Streptoccocus pneumoniae (odds ratio (OR) of 1.0, 95% confidence interval (95% CI) 0.4-2.5); and hypothermic patients (OR = 0.9, 95% CI = 0.3-2.4). Even in patients with septic shock, inappropriate empirical treatment was associated with higher fatality rate (OR = 1.6, 95% CI = 1.0-2.7). The highest benefit associated with appropriate treatment was observed in paediatric patients (OR = 5.1, 95% CI = 2.4-10.7); intra-abdominal infections (OR = 3.8, 95% CI = 2.0-7.1); infections of the skin and soft tissues (OR = 3.1, 95% CI = 1.8-5.6); and infections caused by Klebsiella pneumoniae (OR = 3.0, 95% CI = 1.7-5.1) and S. pneumoniae (OR = 2.6, 95% C = 1.1-5.9). On a multivariable logistic regression analysis, the contribution of inappropriate empirical treatment to fatality was independent of other risk factors (multivariable adjusted OR = 1.6, 95% CI = 1.3-1.9).Appropriate empirical antibiotic treatment was associated with a significant reduction in fatality in patients with bloodstream infection.CONCLUSIONAppropriate empirical antibiotic treatment was associated with a significant reduction in fatality in patients with bloodstream infection. To test whether empirical antibiotic treatment that matches the in vitro susceptibility of the pathogen (appropriate treatment) improves survival in patients with bloodstream infections; and to measure the improvement. Observational, prospective cohort study. University hospital in Israel. All patients with bloodstream infections detected during 1988-94. None. In-hospital fatality rate and length of hospitalization. Out of 2158 patients given appropriate empirical antibiotic treatment, 436 (20%) died, compared with 432 of 1255 patients (34%) given inappropriate treatment (P = 0.0001). The median durations of hospital stay for patients who survived were 9 days for patients given appropriate treatment and 11 days for patients given inappropriate treatment. For patients who died, the median durations were 5 and 4 days, respectively (P < 0.05), for both comparisons. In a stratified analysis, fatality was higher in patients given inappropriate treatment than in those given appropriate treatment in all strata but two: patients with infections caused by streptococci other than Streptococcus gr. A and Streptoccocus pneumoniae (odds ratio (OR) of 1.0, 95% confidence interval (95% CI) 0.4-2.5); and hypothermic patients (OR = 0.9, 95% CI = 0.3-2.4). Even in patients with septic shock, inappropriate empirical treatment was associated with higher fatality rate (OR = 1.6, 95% CI = 1.0-2.7). The highest benefit associated with appropriate treatment was observed in paediatric patients (OR = 5.1, 95% CI = 2.4-10.7); intra-abdominal infections (OR = 3.8, 95% CI = 2.0-7.1); infections of the skin and soft tissues (OR = 3.1, 95% CI = 1.8-5.6); and infections caused by Klebsiella pneumoniae (OR = 3.0, 95% CI = 1.7-5.1) and S. pneumoniae (OR = 2.6, 95% C = 1.1-5.9). On a multivariable logistic regression analysis, the contribution of inappropriate empirical treatment to fatality was independent of other risk factors (multivariable adjusted OR = 1.6, 95% CI = 1.3-1.9). Appropriate empirical antibiotic treatment was associated with a significant reduction in fatality in patients with bloodstream infection. |
Author | Samra Leibovici Pitlik Konigsberger Drucker Shraga |
Author_xml | – sequence: 1 givenname: L surname: LEIBOVICI fullname: LEIBOVICI, L organization: Department of Medicine, Rabin Medical Center, Beilinson Campus, Petah-Tiqva, Israel – sequence: 2 givenname: I surname: SHRAGA fullname: SHRAGA, I organization: Department of Medicine, Rabin Medical Center, Beilinson Campus, Petah-Tiqva, Israel – sequence: 3 givenname: M surname: DRUCKER fullname: DRUCKER, M organization: Infectious Diseases Unit, Rabin Medical Center, Beilinson Campus, Petah-Tiqva, Israel – sequence: 4 givenname: H surname: KONIGSBERGER fullname: KONIGSBERGER, H organization: Infectious Diseases Unit, Rabin Medical Center, Beilinson Campus, Petah-Tiqva, Israel – sequence: 5 givenname: Z surname: SAMRA fullname: SAMRA, Z organization: Microbiology Laboratory, Rabin Medical Center, Beilinson Campus, Petah-Tiqva, Israel – sequence: 6 givenname: S. D surname: PITLIK fullname: PITLIK, S. D organization: Department of Medicine, Rabin Medical Center, Beilinson Campus, Petah-Tiqva, Israel |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2436924$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/9845853$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkUtr3DAUhUVJSSfT_oSCKKU7u3r5oUULIbRJSko26VqVNVdEgy25koYk_75yZphFVtlIF853H5xzhk588IAQpqSmRLRftzXlbVOxTrY1lbKvCeGdrB_foNVROEErIhtRtT0j79BZSltCKCctOUWnshdN3_AV-nt3D3gAD9ZlHCzW8xzDHJ3OgGGaXXRGj1j77AYXsjM4R9B5Ap-x83jW2ZUy4QeX7_EwhrBJCzAV0YLJLvj36K3VY4IPh3-N_vz8cXdxVd3cXl5fnN9URjAiK84GbmwnCDW6By14ZxoihSAgdSNaIHawLTM9NdwSJgYjoNH9hg2Mc9kPHV-jL_u55f5_O0hZTS4ZGEftIeyS6gglHREL-OkFuA276MttispOctY-Qx8P0G6YYKOKI5OOT-rgW9E_H3SdikE2am9cOmJM8FaWZ436PWZiSCmCPRKUqCVItVVLXmrJSy1Bqucg1WNp_f6i1bisF0dz1G58zYBv-wEPboSnVy9Wv26vf5eK_wdMtrfx |
CitedBy_id | crossref_primary_10_1086_503175 crossref_primary_10_1111_aji_12189 crossref_primary_10_1016_j_diagmicrobio_2012_04_006 crossref_primary_10_1177_0885066610371189 crossref_primary_10_1310_hpj4303_199 crossref_primary_10_1128_spectrum_04366_22 crossref_primary_10_2746_042516409X360208 crossref_primary_10_3390_microbiolres14010008 crossref_primary_10_1177_2050312119835043 crossref_primary_10_1016_S0012_3692_15_52948_6 crossref_primary_10_3390_diagnostics13111849 crossref_primary_10_1097_TA_0000000000000309 crossref_primary_10_1007_BF03324619 crossref_primary_10_1016_j_ijantimicag_2009_03_004 crossref_primary_10_1186_s13054_017_1696_z crossref_primary_10_1016_S0873_2159_15_30546_8 crossref_primary_10_1378_chest_06_2535 crossref_primary_10_1007_s00520_012_1572_y crossref_primary_10_1016_j_amjmed_2003_07_005 crossref_primary_10_1016_S0246_0289_08_44773_4 crossref_primary_10_1017_S1481803500012380 crossref_primary_10_1016_S1201_9712_01_90067_0 crossref_primary_10_1016_j_emc_2008_05_004 crossref_primary_10_1186_s12879_020_05550_1 crossref_primary_10_1089_sur_2008_053 crossref_primary_10_1177_175114370400500221 crossref_primary_10_1046_j_1469_0691_2003_00656_x crossref_primary_10_1016_j_apmr_2009_02_012 crossref_primary_10_1177_0897190007311010 crossref_primary_10_1590_S0036_46652014000200002 crossref_primary_10_1016_j_resuscitation_2013_09_022 crossref_primary_10_1097_01_qco_0000393483_10270_ff crossref_primary_10_1016_j_cmi_2016_05_023 crossref_primary_10_1016_S1473_3099_04_01108_9 crossref_primary_10_1111_j_1469_0691_2009_03061_x crossref_primary_10_1016_j_diagmicrobio_2014_01_022 crossref_primary_10_1086_606163 crossref_primary_10_1086_606165 crossref_primary_10_1111_j_1469_0691_2008_01959_x crossref_primary_10_1002_jcla_21571 crossref_primary_10_1093_cid_ciy378 crossref_primary_10_1093_jac_dkn504 crossref_primary_10_1586_erp_10_49 crossref_primary_10_5090_kjtcs_20_111 crossref_primary_10_1053_jhin_2000_0803 crossref_primary_10_1620_tjem_224_61 crossref_primary_10_1016_j_jiac_2020_10_008 crossref_primary_10_1186_cc12705 crossref_primary_10_1592_phco_23_14_1486_31945 crossref_primary_10_1086_590937 crossref_primary_10_1016_j_jcrc_2009_12_004 crossref_primary_10_1186_s13054_019_2632_1 crossref_primary_10_1371_journal_pcbi_1004857 crossref_primary_10_1128_AAC_00851_06 crossref_primary_10_3399_bjgp11X601253 crossref_primary_10_1016_j_bbmt_2014_12_006 crossref_primary_10_1016_S2173_5085_08_70042_X crossref_primary_10_1007_s10096_011_1491_8 crossref_primary_10_1197_j_aem_2004_11_017 crossref_primary_10_1093_epirev_mxab001 crossref_primary_10_3390_diagnostics11122251 crossref_primary_10_1016_j_ijantimicag_2004_11_015 crossref_primary_10_1016_j_diagmicrobio_2015_03_004 crossref_primary_10_1039_D3RA05816F crossref_primary_10_1097_CCM_0b013e31827e83af crossref_primary_10_1097_INF_0b013e31822a37d7 crossref_primary_10_1080_13696998_2023_2169447 crossref_primary_10_1371_journal_pone_0153696 crossref_primary_10_2146_ajhp110332 crossref_primary_10_1016_j_jcrc_2007_08_007 crossref_primary_10_14776_piv_2015_22_3_178 crossref_primary_10_22207_JPAM_12_2_54 crossref_primary_10_1128_JCM_00552_10 crossref_primary_10_1007_s00390_010_0169_2 crossref_primary_10_1378_chest_123_3_854 crossref_primary_10_1097_CCM_0b013e31821e8791 crossref_primary_10_1007_s10096_020_03828_5 crossref_primary_10_1016_j_acci_2018_01_003 crossref_primary_10_2165_11599520_000000000_00000 crossref_primary_10_1007_s10096_011_1503_8 crossref_primary_10_2147_tcrm_2006_2_4_401 crossref_primary_10_1016_S1130_6343_08_75934_8 crossref_primary_10_1097_PCC_0b013e3181b80693 crossref_primary_10_1002_jhm_116 crossref_primary_10_1093_jac_dkt240 crossref_primary_10_1038_s41598_019_51032_z crossref_primary_10_3904_kjim_2016_119 crossref_primary_10_1007_s00134_010_1851_3 crossref_primary_10_1016_j_ijid_2009_11_019 crossref_primary_10_1093_jac_dku336 crossref_primary_10_4161_viru_27409 crossref_primary_10_1016_j_jemermed_2010_10_024 crossref_primary_10_1056_NEJMcpc0807489 crossref_primary_10_1157_13100196 crossref_primary_10_1016_j_ccc_2006_03_005 crossref_primary_10_1016_j_jmii_2013_08_004 crossref_primary_10_1016_j_ncl_2008_03_013 crossref_primary_10_1016_j_suc_2014_10_006 crossref_primary_10_1177_0897190020951348 crossref_primary_10_1016_j_pmrj_2011_03_021 crossref_primary_10_3390_antibiotics8040216 crossref_primary_10_1186_2047_2994_3_32 crossref_primary_10_1016_j_ccc_2006_11_009 crossref_primary_10_1016_j_hrtlng_2015_06_003 crossref_primary_10_1128_Spectrum_00175_21 crossref_primary_10_1097_00003246_200010000_00014 crossref_primary_10_1007_s10096_002_0837_7 crossref_primary_10_1128_JCM_42_3_1337_1340_2004 crossref_primary_10_1016_j_annemergmed_2007_12_013 crossref_primary_10_1177_0310057X0503300504 crossref_primary_10_1016_j_cacc_2005_11_009 crossref_primary_10_1016_S1280_4703_09_70459_1 crossref_primary_10_1016_j_medmal_2010_06_002 crossref_primary_10_1111_jpc_15272 crossref_primary_10_1097_CCM_0000000000003955 crossref_primary_10_3109_00365521_2011_615855 crossref_primary_10_1007_s10096_011_1478_5 crossref_primary_10_1016_j_archger_2010_01_012 crossref_primary_10_3390_jcm9082617 crossref_primary_10_1016_j_suc_2012_08_009 crossref_primary_10_1016_j_idc_2009_01_004 crossref_primary_10_1128_CMR_18_4_638_656_2005 crossref_primary_10_1128_JCM_00047_12 crossref_primary_10_1093_trstmh_tru151 crossref_primary_10_1128_JCM_01831_09 crossref_primary_10_1016_S1473_3099_02_00437_1 crossref_primary_10_1038_sc_2016_38 crossref_primary_10_1111_j_1469_0691_2010_03284_x crossref_primary_10_3389_fcimb_2022_859935 crossref_primary_10_1016_j_ajem_2012_07_024 crossref_primary_10_1111_j_1469_0691_2005_01359_x crossref_primary_10_1016_j_amjsurg_2015_10_025 crossref_primary_10_1128_JCM_44_1_119_123_2006 crossref_primary_10_3390_diagnostics11081514 crossref_primary_10_1093_ajcp_aqv005 crossref_primary_10_1016_j_ijantimicag_2008_03_015 crossref_primary_10_1097_CCM_0b013e3181b033d7 crossref_primary_10_1007_s00508_017_1181_3 crossref_primary_10_1093_cid_ciad243 crossref_primary_10_1002_14651858_CD003344_pub3 crossref_primary_10_1097_CCM_0b013e3181934fab crossref_primary_10_3109_00365548_2012_689848 crossref_primary_10_1016_j_idc_2007_09_005 crossref_primary_10_1016_j_ijmedinf_2004_04_002 crossref_primary_10_1093_jac_dkq069 crossref_primary_10_1016_j_ejim_2011_02_004 crossref_primary_10_1177_00494755221143270 crossref_primary_10_1016_j_medin_2017_07_006 crossref_primary_10_1586_14787210_3_4_593 crossref_primary_10_1002_cncr_27602 crossref_primary_10_1007_s00431_020_03598_4 crossref_primary_10_1017_ice_2020_191 crossref_primary_10_1080_07853890_2017_1332776 crossref_primary_10_1097_CCM_0b013e31820f6d2e crossref_primary_10_1128_CMR_05022_11 crossref_primary_10_1097_CCM_0b013e3182207c13 crossref_primary_10_1111_j_1469_0691_2005_01139_x crossref_primary_10_1016_j_diagmicrobio_2014_03_014 crossref_primary_10_5858_arpa_2013_0681_OA crossref_primary_10_1016_j_cmi_2015_10_034 crossref_primary_10_3947_ic_2012_44_4_275 crossref_primary_10_1086_503342 crossref_primary_10_1093_jac_dks475 crossref_primary_10_1016_S0924_8579_09_70568_0 crossref_primary_10_1378_chest_126_1_173 crossref_primary_10_1128_JCM_05534_11 crossref_primary_10_1111_j_1532_5415_2008_01855_x crossref_primary_10_1592_phco_27_7_1001 crossref_primary_10_1016_j_cger_2007_05_003 crossref_primary_10_1016_S0195_6701_03_00294_9 crossref_primary_10_1007_s00108_006_1595_x crossref_primary_10_1007_s00392_006_0414_7 crossref_primary_10_1007_BF02898020 crossref_primary_10_1097_MD_0000000000033269 crossref_primary_10_1186_s40248_019_0185_4 crossref_primary_10_1002_bdd_666 crossref_primary_10_1542_peds_2007_1387 crossref_primary_10_15324_kjcls_2019_51_2_155 crossref_primary_10_1007_s10096_011_1161_x crossref_primary_10_1016_j_jiac_2023_04_004 crossref_primary_10_1007_s15010_008_8060_9 crossref_primary_10_1016_S1283_0771_09_70288_9 crossref_primary_10_3390_genes14061303 crossref_primary_10_1111_j_1469_0691_2010_03394_x crossref_primary_10_1016_j_ijantimicag_2015_06_016 crossref_primary_10_1016_j_suc_2017_07_003 crossref_primary_10_1016_S0025_7753_08_76461_3 crossref_primary_10_1039_c3an01175e crossref_primary_10_1002_14651858_CD013837_pub2 crossref_primary_10_1080_23744235_2016_1185533 crossref_primary_10_1016_j_amjmed_2019_04_049 crossref_primary_10_1128_AAC_00627_10 crossref_primary_10_1086_518972 crossref_primary_10_1186_s12879_019_4721_9 crossref_primary_10_1007_s00134_005_0064_7 crossref_primary_10_1128_AAC_02462_13 crossref_primary_10_1016_j_diagmicrobio_2011_09_015 crossref_primary_10_1097_01_CCM_0000117317_18092_E4 crossref_primary_10_1016_j_ajic_2007_06_009 crossref_primary_10_1016_j_jmii_2016_06_002 crossref_primary_10_1016_j_tet_2015_09_069 crossref_primary_10_1086_314079 crossref_primary_10_14260_jemds_2018_61 crossref_primary_10_3390_microorganisms10051009 crossref_primary_10_1371_journal_pone_0058418 crossref_primary_10_3390_jcm9010157 crossref_primary_10_1007_s00134_005_2691_4 crossref_primary_10_1016_j_heliyon_2020_e05494 crossref_primary_10_1016_j_ajem_2011_05_029 crossref_primary_10_1093_jac_dkae422 crossref_primary_10_1002_ebch_879 crossref_primary_10_1097_CCM_0b013e318202e68f crossref_primary_10_2165_00003495_200666060_00003 crossref_primary_10_1016_j_diagmicrobio_2003_10_001 crossref_primary_10_1128_AAC_01104_09 crossref_primary_10_1007_s00398_005_0487_z crossref_primary_10_1111_aas_13831 crossref_primary_10_1016_j_amjsurg_2003_03_006 crossref_primary_10_1002_14651858_CD013837 crossref_primary_10_1002_14651858_CD013836 crossref_primary_10_1056_NEJMra043632 crossref_primary_10_3390_jpm13101482 crossref_primary_10_1007_s00423_013_1132_z crossref_primary_10_1128_JCM_38_2_781_788_2000 crossref_primary_10_1155_2014_410430 crossref_primary_10_1007_s00134_009_1608_z crossref_primary_10_1186_1471_2334_13_166 crossref_primary_10_1111_j_1469_0691_2009_02934_x crossref_primary_10_1097_JCMA_0000000000000244 crossref_primary_10_1179_joc_2004_16_3_273 crossref_primary_10_1186_1471_2334_6_24 crossref_primary_10_1371_journal_pntd_0008268 crossref_primary_10_1007_s11845_011_0741_1 crossref_primary_10_1128_AAC_48_12_4606_4610_2004 crossref_primary_10_1080_00365540310012217 crossref_primary_10_1016_j_clinthera_2019_07_010 crossref_primary_10_1155_2018_7013470 crossref_primary_10_1128_AAC_01688_10 crossref_primary_10_1128_JCM_02982_12 crossref_primary_10_1016_j_patbio_2009_08_001 crossref_primary_10_1016_j_bios_2018_12_026 crossref_primary_10_1016_j_jemermed_2012_09_036 crossref_primary_10_1248_bpb_30_2312 crossref_primary_10_1097_01_CCM_0000298158_12101_41 crossref_primary_10_1128_AAC_47_9_2756_2764_2003 crossref_primary_10_1128_JCM_01679_15 crossref_primary_10_1378_chest_09_0087 crossref_primary_10_1016_S1441_2772_23_02101_4 crossref_primary_10_1016_j_ijid_2021_05_079 crossref_primary_10_1016_j_ajem_2011_11_010 crossref_primary_10_1016_j_ijantimicag_2019_05_014 crossref_primary_10_1186_s12879_019_4363_y crossref_primary_10_1016_j_bbmt_2008_10_005 crossref_primary_10_1016_S0002_9343_01_00771_9 crossref_primary_10_1179_1973947815Y_0000000012 crossref_primary_10_1016_j_amjsurg_2003_10_002 crossref_primary_10_1080_00365540310015953 crossref_primary_10_1016_j_ijantimicag_2006_10_017 crossref_primary_10_3390_antibiotics9110807 crossref_primary_10_1093_cid_cit223 crossref_primary_10_1016_j_jinf_2014_09_002 crossref_primary_10_1128_AAC_00466_06 crossref_primary_10_1007_s10096_008_0545_z crossref_primary_10_1086_590061 crossref_primary_10_1186_s12879_017_2233_z crossref_primary_10_1111_j_1469_0691_2004_00914_x crossref_primary_10_1080_00365540151060923 crossref_primary_10_1097_INF_0000000000001204 crossref_primary_10_1177_175114370901000107 crossref_primary_10_1093_cid_cir051 crossref_primary_10_1109_69_868905 crossref_primary_10_1378_chest_118_1_146 crossref_primary_10_1086_379825 crossref_primary_10_1128_AAC_00385_10 crossref_primary_10_1097_01_inf_0000157086_97503_bd crossref_primary_10_2165_00003495_200767030_00003 crossref_primary_10_1086_525536 crossref_primary_10_1016_j_pharma_2012_10_002 crossref_primary_10_1007_s10096_017_3136_z crossref_primary_10_1097_CCM_0000000000000509 crossref_primary_10_1097_PEC_0000000000001835 crossref_primary_10_1128_genomeA_00112_13 crossref_primary_10_1128_AAC_01586_17 crossref_primary_10_1128_AAC_49_2_760_766_2005 crossref_primary_10_1177_1062860614551042 crossref_primary_10_1080_10245332_2016_1253521 crossref_primary_10_1136_jcp_2008_055681 crossref_primary_10_1093_jac_dkp004 crossref_primary_10_1097_01_CCM_0000202128_30405_60 crossref_primary_10_1007_s10439_019_02256_7 crossref_primary_10_1097_01_CCM_0000206104_18647_A8 crossref_primary_10_1128_AAC_00338_07 crossref_primary_10_1016_j_jgo_2018_06_011 crossref_primary_10_1089_sur_2006_072 crossref_primary_10_1586_14737167_6_1_49 crossref_primary_10_1007_s10096_016_2701_1 crossref_primary_10_1016_j_ccc_2006_02_006 crossref_primary_10_1016_j_diagmicrobio_2018_11_009 crossref_primary_10_1093_cid_cis1204 crossref_primary_10_2165_00003088_200544100_00002 crossref_primary_10_1016_j_burns_2009_07_010 crossref_primary_10_1007_s15010_023_02105_9 crossref_primary_10_1007_s10096_018_3211_0 crossref_primary_10_1016_S0399_077X_02_00440_7 crossref_primary_10_1016_j_ccc_2010_09_007 crossref_primary_10_12677_acm_2024_1441211 crossref_primary_10_1371_journal_pone_0011432 crossref_primary_10_3390_ph12010035 crossref_primary_10_1007_s10096_018_3343_2 crossref_primary_10_1186_s13756_019_0485_7 crossref_primary_10_1038_bmt_2014_37 crossref_primary_10_1007_s11606_024_09119_5 crossref_primary_10_1086_431672 crossref_primary_10_1111_j_1469_0691_2009_02736_x crossref_primary_10_1016_j_jcrc_2008_12_012 crossref_primary_10_1093_jac_dkm193 crossref_primary_10_1111_aas_13418 crossref_primary_10_1007_s15010_008_6306_1 crossref_primary_10_1053_j_sane_2004_11_009 crossref_primary_10_1016_j_ijantimicag_2019_105860 crossref_primary_10_1016_j_mcp_2005_07_005 crossref_primary_10_2165_00003495_200363200_00001 crossref_primary_10_1007_s00134_007_0934_2 crossref_primary_10_1097_01_CCM_0000055381_70829_94 crossref_primary_10_1128_AAC_00834_09 crossref_primary_10_1016_j_ijantimicag_2005_01_019 crossref_primary_10_1016_j_ijid_2020_08_013 crossref_primary_10_1007_s00134_004_2210_z crossref_primary_10_1016_j_cll_2013_03_013 crossref_primary_10_1097_SHK_0000000000000192 crossref_primary_10_1086_524330 crossref_primary_10_1099_jmm_0_000259 crossref_primary_10_1345_aph_1Q403 crossref_primary_10_1016_j_nano_2016_09_005 crossref_primary_10_1007_s15010_022_01973_x crossref_primary_10_1093_jac_dkr511 crossref_primary_10_1086_502469 crossref_primary_10_1128_CMR_00095_17 crossref_primary_10_3182_20090812_3_DK_2006_0103 crossref_primary_10_1016_j_immbio_2009_06_004 crossref_primary_10_1097_INF_0b013e318158603a crossref_primary_10_1378_chest_125_5_1600 crossref_primary_10_1128_JCM_01084_14 crossref_primary_10_1007_s10096_022_04419_2 crossref_primary_10_1186_cc2358 crossref_primary_10_3201_eid1808_111234 crossref_primary_10_3201_eid0812_020139 crossref_primary_10_1002_14651858_CD005197_pub3 crossref_primary_10_1007_s10156_008_0655_7 crossref_primary_10_1186_s13643_019_1207_1 crossref_primary_10_1016_j_ijantimicag_2008_07_023 crossref_primary_10_1001_jamanetworkopen_2018_3927 crossref_primary_10_1128_AAC_50_5_1715_1720_2006 crossref_primary_10_1097_01_ccx_0000235211_79236_83 crossref_primary_10_1378_chest_123_5_suppl_464S crossref_primary_10_1007_s10096_018_3430_4 crossref_primary_10_1016_S0304_5412_11_70225_6 crossref_primary_10_1016_j_ijantimicag_2010_11_010 crossref_primary_10_1128_JCM_02523_06 crossref_primary_10_1186_s12879_020_05262_6 crossref_primary_10_3947_ic_2024_0026 crossref_primary_10_1086_515403 crossref_primary_10_1007_s00134_008_1268_4 crossref_primary_10_1016_j_ccc_2010_11_001 crossref_primary_10_7883_yoken_JJID_2014_573 crossref_primary_10_1016_j_cmpb_2010_06_018 crossref_primary_10_1128_mBio_00102_17 crossref_primary_10_1097_CCM_0b013e3181e6a2a4 crossref_primary_10_1111_jcpt_13818 crossref_primary_10_1592_phco_31_5_469 crossref_primary_10_1016_j_ijantimicag_2008_07_007 crossref_primary_10_1007_s00134_012_2769_8 crossref_primary_10_1016_j_clinbiochem_2009_12_007 crossref_primary_10_1186_s12866_024_03249_w crossref_primary_10_1177_0897190005282174 crossref_primary_10_1111_1469_0691_12329 crossref_primary_10_1186_s13054_015_0795_y crossref_primary_10_1016_j_jhin_2017_03_016 crossref_primary_10_1007_s15010_023_02073_0 crossref_primary_10_1097_SHK_0000000000000833 crossref_primary_10_1097_CNQ_0000000000000053 crossref_primary_10_1179_146532809X440716 crossref_primary_10_1016_j_ijantimicag_2007_06_035 crossref_primary_10_1128_AAC_01645_10 crossref_primary_10_1071_HI09012 crossref_primary_10_1373_clinchem_2004_032144 crossref_primary_10_1016_S0188_4409_01_00380_0 crossref_primary_10_3389_fmed_2022_869822 crossref_primary_10_1007_s10096_016_2686_9 crossref_primary_10_1007_s00101_010_1719_5 crossref_primary_10_1086_375057 crossref_primary_10_1016_j_medine_2017_07_003 crossref_primary_10_4103_jpbs_JPBS_478_20 crossref_primary_10_1080_07853890_2021_1953703 crossref_primary_10_1186_1471_2334_13_500 crossref_primary_10_1016_j_jemermed_2015_01_001 crossref_primary_10_1378_chest_07_0005 crossref_primary_10_4103_0255_0857_62491 crossref_primary_10_1016_j_jemermed_2012_11_112 crossref_primary_10_1097_01_CCM_0000143118_41100_14 crossref_primary_10_1186_s13027_017_0150_9 crossref_primary_10_1016_S1473_3099_09_70135_5 crossref_primary_10_1128_AAC_01388_12 crossref_primary_10_1097_00003246_200107000_00029 crossref_primary_10_1186_1471_2334_8_116 crossref_primary_10_1016_j_diagmicrobio_2005_02_007 crossref_primary_10_1016_j_mimet_2013_02_005 crossref_primary_10_1093_jac_dkn357 crossref_primary_10_1186_s13643_024_02695_x crossref_primary_10_1016_j_medmal_2011_05_003 crossref_primary_10_1310_hpj4507_538 crossref_primary_10_1016_j_jinf_2009_03_001 crossref_primary_10_1186_1471_2334_7_106 crossref_primary_10_1111_j_1469_0691_2006_01556_x crossref_primary_10_1128_AAC_00063_08 crossref_primary_10_12968_hmed_2005_66_3_17684 crossref_primary_10_1016_j_cmi_2019_06_034 crossref_primary_10_1111_j_1600_6143_2009_02664_x crossref_primary_10_1016_j_ijantimicag_2007_06_013 crossref_primary_10_1111_j_1469_0691_2010_03330_x crossref_primary_10_1177_0310057X1204000509 crossref_primary_10_1186_s12879_024_10293_4 crossref_primary_10_1080_00365540110080827 crossref_primary_10_1086_522772 crossref_primary_10_1016_j_annemergmed_2006_02_015 crossref_primary_10_1007_s00390_006_0700_7 crossref_primary_10_1111_ggi_12866 crossref_primary_10_1016_j_jemermed_2006_05_008 crossref_primary_10_1592_phco_24_18_216S_52237 crossref_primary_10_1186_s12879_023_08498_0 crossref_primary_10_1016_j_ijantimicag_2012_06_022 crossref_primary_10_1002_jhm_980 crossref_primary_10_1089_sur_2014_180 crossref_primary_10_1016_j_ccm_2008_09_005 crossref_primary_10_1016_j_ijantimicag_2017_12_013 crossref_primary_10_1016_j_jemermed_2012_11_051 crossref_primary_10_1016_j_clinthera_2005_11_007 crossref_primary_10_1007_s10096_008_0515_5 crossref_primary_10_1128_JCM_43_4_1947_1949_2005 crossref_primary_10_1007_s10156_012_0423_6 crossref_primary_10_1097_00003246_200104001_00011 crossref_primary_10_1097_00003246_200104001_00012 crossref_primary_10_1097_00003246_200104001_00014 crossref_primary_10_1111_j_1553_2712_2005_tb01957_x crossref_primary_10_1128_AAC_00601_06 crossref_primary_10_1097_00003246_200104001_00008 crossref_primary_10_1128_CMR_00043_09 crossref_primary_10_1007_s10156_010_0069_1 crossref_primary_10_1128_JCM_01835_13 crossref_primary_10_1016_j_clinbiochem_2012_03_030 crossref_primary_10_1086_674849 crossref_primary_10_1186_s12887_024_04793_0 crossref_primary_10_1093_jac_dkm354 crossref_primary_10_1111_j_1532_5415_2010_03289_x crossref_primary_10_1128_AAC_01481_13 crossref_primary_10_1080_1120009X_2016_1182770 crossref_primary_10_1093_cid_ciy790 crossref_primary_10_1016_S0210_5691_05_74278_9 crossref_primary_10_1046_j_1532_5415_2002_50458_x crossref_primary_10_3389_fphar_2024_1329307 crossref_primary_10_1111_j_1348_0421_2011_00373_x crossref_primary_10_1097_SMJ_0b013e31816c00fa crossref_primary_10_1186_s12866_023_02893_y crossref_primary_10_1097_01_CCM_0000239121_09533_09 crossref_primary_10_1016_j_ajem_2014_11_024 crossref_primary_10_1177_0300060519829987 crossref_primary_10_1007_s00390_006_0657_6 crossref_primary_10_1128_AAC_01050_17 crossref_primary_10_1093_jac_dkl372 crossref_primary_10_1371_journal_pone_0007782 crossref_primary_10_1128_AAC_00810_07 crossref_primary_10_1016_j_ijantimicag_2021_106379 crossref_primary_10_1016_S1473_3099_05_70031_1 crossref_primary_10_1007_s00296_014_3206_9 crossref_primary_10_1179_acb_2005_011 crossref_primary_10_1097_01_CCM_0000050298_59549_4A crossref_primary_10_1111_j_1469_0691_2009_02754_x crossref_primary_10_1128_JCM_02322_13 crossref_primary_10_1378_chest_130_6_1672 crossref_primary_10_1055_s_0040_1714199 crossref_primary_10_1007_s10096_014_2146_3 crossref_primary_10_1016_j_jeur_2007_01_005 crossref_primary_10_1089_sur_2014_096 crossref_primary_10_1177_0885066611408690 crossref_primary_10_1093_ajhp_62_5_499 crossref_primary_10_1016_j_jpedsurg_2010_12_001 crossref_primary_10_3343_lmo_2019_9_2_63 crossref_primary_10_1002_jppr_1207 crossref_primary_10_1016_j_jri_2021_103460 crossref_primary_10_1093_infdis_jiv429 crossref_primary_10_1111_j_1574_6976_2011_00298_x crossref_primary_10_4065_mcp_2011_0415 crossref_primary_10_1186_1471_2334_9_126 crossref_primary_10_1002_14651858_CD013836_pub2 crossref_primary_10_3109_00365548_2013_782102 |
Cites_doi | 10.1093/qjmed/89.7.515 10.1093/jac/18.Supplement_C.255 10.1001/jama.1996.03530270029027 10.1056/NEJM199404283301725 10.3109/00365549109075086 10.1093/clinids/5.4.629 10.1016/0002-9343(89)90333-1 10.1016/S0140-6736(94)90694-7 10.1001/archinte.1985.00360070082014 10.7326/0003-4819-123-4-199508150-00002 10.1001/archinte.1995.00430110089009 10.1093/clinids/19.2.246 10.1001/jama.1995.03530100047033 10.1111/j.1365-2796.1992.tb00946.x 10.1093/clinids/12.6.1008 10.1093/clinids/5.1.54 10.7326/0003-4819-124-10-199605150-00004 |
ContentType | Journal Article |
Copyright | Blackwell Science Ltd, 1997 1998 INIST-CNRS Copyright Blackwell Scientific Publications Ltd. Nov 1998 |
Copyright_xml | – notice: Blackwell Science Ltd, 1997 – notice: 1998 INIST-CNRS – notice: Copyright Blackwell Scientific Publications Ltd. Nov 1998 |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7QL C1K K9. 7X8 |
DOI | 10.1046/j.1365-2796.1998.00379.x |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Environmental Sciences and Pollution Management ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Bacteriology Abstracts (Microbiology B) Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1365-2796 |
EndPage | 386 |
ExternalDocumentID | 36164725 9845853 2436924 10_1046_j_1365_2796_1998_00379_x JOIM379 |
Genre | article Journal Article |
GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 24P 29K 2WC 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AASGY AAWTL AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHEFC AI. AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F D-I DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 DUUFO E3Z EBS EJD EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FIJ FUBAC G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IPNFZ IX1 J0M KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SJN SUPJJ TEORI TR2 UB1 V8K V9Y VH1 VVN W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR X7M XG1 YFH YOC YUY ZCG ZGI ZXP ZZTAW ~IA ~WT AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY IQODW CGR CUY CVF ECM EIF NPM 7QL C1K K9. 7X8 |
ID | FETCH-LOGICAL-c4209-32b3cf7401ca8ea437c509440e9a546e0fbf62c81c3f024bc4e5a8d2b23398b73 |
IEDL.DBID | DR2 |
ISSN | 0954-6820 |
IngestDate | Fri Jul 11 12:24:28 EDT 2025 Sat Jul 26 02:30:21 EDT 2025 Thu Apr 03 07:03:25 EDT 2025 Mon Jul 21 09:16:04 EDT 2025 Tue Jul 01 04:07:20 EDT 2025 Thu Apr 24 23:11:00 EDT 2025 Wed Jan 22 16:59:16 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | Human Septicemia Mortality Empirical method Bacteremia Infection Prospective Antibiotic Chemotherapy Treatment Cohort study Bacteriosis Profit |
Language | English |
License | http://onlinelibrary.wiley.com/termsAndConditions#vor CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4209-32b3cf7401ca8ea437c509440e9a546e0fbf62c81c3f024bc4e5a8d2b23398b73 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-2 content type line 23 |
PMID | 9845853 |
PQID | 197932647 |
PQPubID | 30713 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_70107047 proquest_journals_197932647 pubmed_primary_9845853 pascalfrancis_primary_2436924 crossref_primary_10_1046_j_1365_2796_1998_00379_x crossref_citationtrail_10_1046_j_1365_2796_1998_00379_x wiley_primary_10_1046_j_1365_2796_1998_00379_x_JOIM379 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 1900 |
PublicationDate | November 1998 |
PublicationDateYYYYMMDD | 1998-11-01 |
PublicationDate_xml | – month: 11 year: 1998 text: November 1998 |
PublicationDecade | 1990 |
PublicationPlace | Oxford BSL |
PublicationPlace_xml | – name: Oxford BSL – name: Oxford – name: England |
PublicationTitle | Journal of internal medicine |
PublicationTitleAlternate | J Intern Med |
PublicationYear | 1998 |
Publisher | Blackwell Science Ltd Blackwell Science Blackwell Publishing Ltd |
Publisher_xml | – name: Blackwell Science Ltd – name: Blackwell Science – name: Blackwell Publishing Ltd |
References | 1994; 344 1994; 330 1990; 12 1989; 86 1987; 63 1991; 23 1994; 19 1992; 231 1983; 5 1985; 145 1986; 18 1996; 275 1995; 155 1992; 49 1995; 123 1995; 274 1996; 124 1996; 89 e_1_2_5_14_2 e_1_2_5_13_2 e_1_2_5_16_2 McCue JD (e_1_2_5_17_2) 1985; 145 e_1_2_5_8_2 e_1_2_5_15_2 e_1_2_5_5_2 e_1_2_5_12_2 e_1_2_5_20_2 e_1_2_5_11_2 e_1_2_5_21_2 e_1_2_5_3_2 e_1_2_5_2_2 e_1_2_5_18_2 Berman JR (e_1_2_5_10_2) 1992; 49 e_1_2_5_19_2 Pinner RW (e_1_2_5_9_2) 1996; 275 Pittet D (e_1_2_5_6_2) 1995; 155 Ispahani P (e_1_2_5_4_2) 1987; 63 Leibovici L (e_1_2_5_7_2) 1995; 274 |
References_xml | – volume: 275 start-page: 189 year: 1996 end-page: 93 article-title: Trends in infectious diseases mortality in the United States. publication-title: JAMA – volume: 5 start-page: 54 year: 1983 end-page: 70 article-title: The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungaemia in adults. II. Clinical observations, with special reference to factors influencing prognosis. publication-title: Rev Infect Dis – volume: 155 start-page: 1177 year: 1995 end-page: 84 article-title: Nosocomial bloodstream infections: secular trends in rates, mortality, and contribution to total hospital deaths. publication-title: Arch Intern Med – volume: 86 start-page: 379 year: 1989 end-page: 84 article-title: Bloodstream infections in the elderly. publication-title: Am J Med – volume: 274 start-page: 807 year: 1995 end-page: 12 article-title: Long‐term survival following bacteremia or fungemia. publication-title: JAMA – volume: 12 start-page: 1008 year: 1990 end-page: 18 article-title: Bacteremia due to . A study 861 episodes. publication-title: Rev Infect Dis – volume: 89 start-page: 515 year: 1996 end-page: 22 article-title: The systemic inflammatory response syndrome as predictor of bacteraemia and outcome from sepsis. publication-title: Q J Med – volume: 124 start-page: 884 year: 1996 end-page: 90 article-title: Implementing antibiotic practice guidelines through computer‐assisted decision support: clinical and financial outcomes. publication-title: Ann Intern Med – volume: 19 start-page: 246 year: 1994 end-page: 56 article-title: Bloodstream infections at a Norwegian university hospital. 1974–79 and 1988–89: changing etiology, clinical features and outcome. publication-title: Clin Infect Dis – volume: 18 start-page: 255 year: 1986 end-page: 60 article-title: Resistance as a cause of treatment failure. publication-title: J Antimicrob Chemother – volume: 49 start-page: 1701 year: 1992 end-page: 6 article-title: Pharmacy‐based antimicrobial‐monitoring service. publication-title: Am J Hosp Pharm – volume: 344 start-page: 1329 year: 1994 end-page: 32 article-title: Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam. publication-title: Lancet – volume: 145 start-page: 1212 year: 1985 end-page: 6 article-title: Improved mortality in gram‐negative bacillary bacteremia. publication-title: Arch Intern Med – volume: 330 start-page: 1247 year: 1994 end-page: 51 article-title: Multiple antibiotic resistant pathogenic bacteria. publication-title: N Engl J Med – volume: 123 start-page: 250 year: 1995 end-page: 9 article-title: Enterococci resistant to multiple antimicrobial agents, including vancomycin: establishment of endemicity in a university medical center. publication-title: Ann Intern Med – volume: 23 start-page: 399 year: 1991 end-page: 405 article-title: Klebsiella bacteremia: a review of 196 episodes during a decade (1980–89). publication-title: Scand J Infect Dis – volume: 231 start-page: 371 year: 1992 end-page: 4 article-title: Patients at risk for inappropriate antibiotic treatment of bacteremia. publication-title: J Intern Med – volume: 5 start-page: 629 year: 1983 end-page: 38 article-title: Analysis of 1,186 episodes of gram‐negative bacteremia in non‐university hospitals: the effects of antimicrobial therapy. publication-title: Rev Infect Dis – volume: 63 start-page: 427 year: 1987 end-page: 40 article-title: An analysis of community and hospital‐acquired bacteraemia in a large teaching hospital in the United Kingdom. publication-title: Q J Med – volume: 49 start-page: 1701 year: 1992 ident: e_1_2_5_10_2 article-title: Pharmacy‐based antimicrobial‐monitoring service. publication-title: Am J Hosp Pharm – volume: 63 start-page: 427 year: 1987 ident: e_1_2_5_4_2 article-title: An analysis of community and hospital‐acquired bacteraemia in a large teaching hospital in the United Kingdom. publication-title: Q J Med – ident: e_1_2_5_8_2 doi: 10.1093/qjmed/89.7.515 – ident: e_1_2_5_21_2 doi: 10.1093/jac/18.Supplement_C.255 – volume: 275 start-page: 189 year: 1996 ident: e_1_2_5_9_2 article-title: Trends in infectious diseases mortality in the United States. publication-title: JAMA doi: 10.1001/jama.1996.03530270029027 – ident: e_1_2_5_20_2 – ident: e_1_2_5_12_2 doi: 10.1056/NEJM199404283301725 – ident: e_1_2_5_18_2 doi: 10.3109/00365549109075086 – ident: e_1_2_5_2_2 doi: 10.1093/clinids/5.4.629 – ident: e_1_2_5_15_2 doi: 10.1016/0002-9343(89)90333-1 – ident: e_1_2_5_14_2 doi: 10.1016/S0140-6736(94)90694-7 – volume: 145 start-page: 1212 year: 1985 ident: e_1_2_5_17_2 article-title: Improved mortality in gram‐negative bacillary bacteremia. publication-title: Arch Intern Med doi: 10.1001/archinte.1985.00360070082014 – ident: e_1_2_5_13_2 doi: 10.7326/0003-4819-123-4-199508150-00002 – volume: 155 start-page: 1177 year: 1995 ident: e_1_2_5_6_2 article-title: Nosocomial bloodstream infections: secular trends in rates, mortality, and contribution to total hospital deaths. publication-title: Arch Intern Med doi: 10.1001/archinte.1995.00430110089009 – ident: e_1_2_5_5_2 doi: 10.1093/clinids/19.2.246 – volume: 274 start-page: 807 year: 1995 ident: e_1_2_5_7_2 article-title: Long‐term survival following bacteremia or fungemia. publication-title: JAMA doi: 10.1001/jama.1995.03530100047033 – ident: e_1_2_5_19_2 doi: 10.1111/j.1365-2796.1992.tb00946.x – ident: e_1_2_5_16_2 doi: 10.1093/clinids/12.6.1008 – ident: e_1_2_5_3_2 doi: 10.1093/clinids/5.1.54 – ident: e_1_2_5_11_2 doi: 10.7326/0003-4819-124-10-199605150-00004 |
SSID | ssj0013060 |
Score | 2.1614134 |
Snippet | . Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD (Rabin Medical Center, Petah‐Tiqva, and Tel‐Aviv University, Tel‐Aviv, Israel). The... To test whether empirical antibiotic treatment that matches the in vitro susceptibility of the pathogen (appropriate treatment) improves survival in patients... |
SourceID | proquest pubmed pascalfrancis crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 379 |
SubjectTerms | Adolescent Adult Aged Aged, 80 and over Anti-Bacterial Agents - therapeutic use Antibacterial agents antibiotic treatment Antibiotics. Antiinfectious agents. Antiparasitic agents bacteraemia Biological and medical sciences bloodstream infection Child Child, Preschool empirical fatality rate Female Humans Infant Infant, Newborn Logistic Models Male Medical sciences Middle Aged Pharmacology. Drug treatments Prospective Studies Risk Factors Sepsis - drug therapy Sepsis - mortality Treatment Outcome |
Title | The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1046%2Fj.1365-2796.1998.00379.x https://www.ncbi.nlm.nih.gov/pubmed/9845853 https://www.proquest.com/docview/197932647 https://www.proquest.com/docview/70107047 |
Volume | 244 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Na9wwEBUlh1IobfoR6iZpdejVi1cflnQsISEJbAulgdxUSSuDSeNdsl4o_fWdkWWXDTmE0osx2BL2eCQ9ed68IeQTl9E5qUwpvGRwMAbmwcDKioc6VG4uY8BE4cWX-vxKXF7L68x_wlyYQR9i-uGGIyPN1zjAnR-qkFRJ3XZkaClTY8odUiK5MjPEk3gB8dE39jegUKWEYQAUoqxh1cuknhzgfLCjnZXq-dptwGjNUO3iITi6i27T8nT2ktyMLzawUm5m297Pwu97mo__5833yYuMYunnwe1ekSexe02eLnKc_g35Ad5HPUyjTdvTVUOTcvkafL2PNN6u26RLQuGjtr5dQR904rvTtqNZ63VD8ScxTdR6TGlxt3SkjnVvydXZ6feT8zLXciiDYEivYJ6HBsv_BaejE1wFlO4TVTROijpWjW9qFvQ88AZggw8iSqeXzDPOjfaKH5C9btXFd4Q6JyTAlqWBzbXQS-Ej08EpLfUcwNMyFkSN382GLHSO9TZ-2hRwF5ichga0aECLBrTJgPZXQeZTy_Ug9vGINsc7rjE1ZILXsLktyOHoKjZPDxvoQCFuFqogH6erMK4xWOO6uNpurIKNsqrwjoPBv6aOjRawx-MFqZOTPPpJ7eXXiwWcvf_XhofkWcrITJmYR2Svv9vGY4Bkvf-QBtsf8z8niA |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3da9swEBejhW1Qus8yt-uqh706c_RhWY9lrKRd08FooW-apMhg2jphcaDsr9-drHhk9KGMvQRDLGGf76Tf6e53R8hHLoO1UulcOMngR2tYBz3LC-5LX9ixDB6JwtOLcnIlzq7ldWoHhFyYvj7EcOCGlhHXazRwPJD-lMKSvZX3hCpdIucOcyK50iMAlNvY4Dv6V9_Zn5BCESnDAClEXsK-l9J6UojzwZk29qqdhV2C2Oq-38VDgHQT38YN6uQFuV2_Wp-XcjNadW7kf_1V9fE_vftLspuALD3uNe8VeRLa1-TpNIXq35AfoIDUwUpaNx2d1zQWL1-AuneBhrtFE0uTUPiujWvmMAcdUt5p09JU7nVJ8ZyYxux6ZLXYO7rOHmvfkquTL5efJ3lq55B7wTDDgjnua-wA6G0VrODKY_U-UQRtpShDUbu6ZL4ae14DcnBeBGmrGXOMc105xffIVjtvwztCrRUSkMtMg38tqplwgVXeqkpWY8BPs5ARtf5wxqda59hy49bEmLtAfhoK0KAADQrQRAGa-4yMh5GLvt7HI8YcbujGMJAJXoJ_m5GDta6YtEIsYQKF0FmojBwN_4JpY7zGtmG-WhoFvrIq8I69XsGGiXUlwM3jGSmjljz6Sc3Zt9MpXO3_68Aj8mxyOT0356cXXw_I80jQjMTM92Sr-7kKh4DQOvchWt5vaGIrow |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlhVAofYc6j0aHXr31SrIlH0uTJUm7aSkN5KZKsgwmjdd0vRDy6zMja1225BBKL8ZgS1jjGekbzXwjQt7z3BuTyzIVNmdwKUuYBx1LM-4Kl5lp7h0ShefnxcmFOLvML2P-E3JhhvoQ44YbWkaYr9HAu6r-EKOSg5EPfKqyQModpkRyWU4ATz4WRaZQw4--sz8RhSwwhgFRiLSAZS9m9cQI5709bSxVTzuzBKnVw3EX9-HRTXgb1qfZc3K1HtmQlnI1WfV24m7_Kvr4f4b-gjyLMJZ-HPTuJXnk21dkex4D9a_JT1A_amEerZueLmoaSpd3oOy9p_66a0JhEgp_tbHNAvqgY8I7bVoai70uKe4S05Bbj5wWc03XuWPtG3IxO_7x6SSNhzmkTjDMr2CWuxrP_3NGeSO4dFi7T2S-NLkofFbbumBOTR2vATdYJ3xuVMUs47xUVvIdstUuWv-WUGNEDrilKsG7FqoS1jPljFS5mgJ6qnxC5Pq_aRcrneOBG790iLgLZKehADUKUKMAdRCgvknIdGzZDdU-HtDmYEM1xoZM8AK824TsrVVFx_lhCR1IBM5CJuRwfAqGjdEa0_rFaqkleMoywzd2Bv0aOy6VACePJ6QISvLgL9VnX0_ncLf7rw0Pyfa3o5n-cnr-eY88CezMwMrcJ1v975U_AHjW23fB7u4A0ccqWw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+benefit+of+appropriate+empirical+antibiotic+treatment+in+patients+with+bloodstream+infection&rft.jtitle=Journal+of+internal+medicine&rft.au=Leibovici&rft.au=Shraga&rft.au=Drucker&rft.au=Konigsberger&rft.date=1998-11-01&rft.issn=0954-6820&rft.eissn=1365-2796&rft.volume=244&rft.issue=5&rft.spage=379&rft.epage=386&rft_id=info:doi/10.1046%2Fj.1365-2796.1998.00379.x&rft.externalDBID=n%2Fa&rft.externalDocID=10_1046_j_1365_2796_1998_00379_x |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0954-6820&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0954-6820&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0954-6820&client=summon |